Pfizer (PFE) stock in focus as Priovant, a partnership between the company and Roivant Sciences (ROIV) posts positive trial ...

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

By Mrinalika Roy and Michael Erman Feb 3(Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug from ...

Pfizer's latest trial data on a new obesity drug raises questions about its tolerability, leading to a slight drop in the ...

Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...